Inventor · disambiguated record
Webster K. Cavenee
Also filed as: CAVENEE WEBSTER · CAVENEE WEBSTER K
9 granted patents·15 pending applications·125 citations·filing 1994–2023
87Inventor score
Files withALNYLAM PHARMACEUTICALS INC5LUDWIG INST CANCER RES5LUDWIG INST FOR CANCER RES LTD4JOHNS TERRANCE GRANT3SAH DINAH2
Top patents by PatentIndex Score
24 records- 0195US7589180B2Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Sep 15, 2009·70 cites·4 claims
- 0291US9212364B2Compositions and methods for inhibiting expression of mutant EGFR geneSAH DINAH·Filed 2012·Granted Dec 15, 2015·24 cites·21 claims
- 0386US2024401060A1Compositions and methods for inhibiting expression of mutant egfr geneALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0484US9562102B2Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2012·Granted Feb 7, 2017·3 cites·2 claims
- 0584US2024117073A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2023·Application pending·0 cites
- 0679US2023053332A1Compositions and methods for inhibiting expression of mutant egfr geneALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0772US9023356B2Treatment method using EGFR antibodies and SRC inhibitors and related formulationsJOHNS TERRANCE GRANT·Filed 2008·Granted May 5, 2015·2 cites·14 claims
- 0871US2021032366A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2020·Application pending·0 cites
- 0970US2020377893A1Compositions and methods for inhibiting expression of mutant egfr geneALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1069US8318693B2Compositions and methods for inhibiting expression of mutant EGFR geneSAH DINAH·Filed 2009·Granted Nov 27, 2012·0 cites·20 claims
- 1164US2009220510A1Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2008·Application pending·0 cites
- 1263US2019010502A1Compositions and methods for inhibiting expression of mutant egfr geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1361US2018057606A1Methods of treating meningiomaLUDWIG INST FOR CANCER RES LTD·Filed 2017·Application pending·0 cites
- 1460US6444640B1Compositions of trail and DNA damaging drugs and uses thereofLUDWIG INST CANCER RES·Filed 1999·Granted Sep 3, 2002·24 cites·9 claims
- 1559US2024093303A1Methods and biomarkers in cancerUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 1658US9957507B2Compositions and methods for inhibiting expression of mutant EGFR geneALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted May 1, 2018·0 cites·25 claims
- 1755US2016046726A1Specific binding proteins and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2015·Application pending·0 cites
- 1851US2011313230A1Specific binding proteins and uses thereofJOHNS TERRANCE GRANT·Filed 2011·Application pending·0 cites
- 1942US2011293511A1Specific binding proteins and uses thereofJOHNS TERRANCE GRANT·Filed 2011·Application pending·0 cites
- 2037US2011076232A1Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2010·Application pending·0 cites
- 2136US2012165340A1Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosisFURNARI FRANK·Filed 2010·Application pending·0 cites
- 2229US5807731AGlioblastoma cell lines that produce angiogenesis inhibiting factorUNIV CALIFORNIA AT SAN DIEGO·Filed 1994·Granted Sep 15, 1998·1 cites·6 claims
- 2327US5990280AGlioblastoma-derived angiogenesis inhibiting factorLUDWIG INSTITUE FOR CANCER RES·Filed 1995·Granted Nov 23, 1999·1 cites·1 claims
- 2423US2001051628A1Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptorsFiled 1998·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →